Evercore ISI Group Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $125
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Michael DiFiore maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $123 to $125.
Evercore ISI Group analyst Michael DiFiore maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $123 to $125.